Computer-guided design of optimal microbial consortia for immune system modulation

  1. Richard R Stein  Is a corresponding author
  2. Takeshi Tanoue
  3. Rose L Szabady
  4. Shakti K Bhattarai
  5. Bernat Olle
  6. Jason M Norman
  7. Wataru Suda
  8. Kenshiro Oshima
  9. Masahira Hattori
  10. Georg K Gerber
  11. Chris Sander
  12. Kenya Honda
  13. Vanni Bucci  Is a corresponding author
  1. Dana-Farber Cancer Institute, United States
  2. RIKEN Institute, Japan
  3. Vedanta Biosciences, Inc, United States
  4. University of Massachusetts, United States
  5. Keio University School of Medicine, Japan
  6. The University of Tokyo, Japan
  7. Brigham and Women's Hospital, United States

Abstract

Manipulation of the gut microbiota holds great promise for the treatment of diseases. However, a major challenge is the identification of therapeutically potent microbial consortia that colonize the host effectively while maximizing immunologic outcome. Here, we propose a novel workflow to select optimal immune-inducing consortia from microbiome composition and immune effectors measurements. Using published and newly generated microbial and regulatory T-cell (Treg) data from germ-free mice, we estimate the contribution of twelve Clostridia strains with known immune-modulating effect to Treg induction. Combining this with a longitudinal data-constrained ecological model, we predict the ability of every attainable and ecologically stable subconsortium in promoting Treg activation and rank them by the Treg Induction Score (TrIS). Experimental validation of selected consortia indicates a strong and statistically significant correlation between predicted TrIS and measured Treg. We argue that computational indexes, such as the TrIS, are valuable tools for the systematic selection of immune-modulating bacteriotherapeutics.

Data availability

The following previously published data sets were used

Article and author information

Author details

  1. Richard R Stein

    Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, United States
    For correspondence
    stein@jimmy.harvard.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5110-6863
  2. Takeshi Tanoue

    Center for Integrative Medical Sciences, RIKEN Institute, Yokohama City, Japan
    Competing interests
    Takeshi Tanoue, Has received support from Vedanta Biosciences, Inc. under research agreement with his institution.
  3. Rose L Szabady

    Vedanta Biosciences, Inc, Cambridge, United States
    Competing interests
    Rose L Szabady, Is employee of Vedanta Biosciences, Inc.
  4. Shakti K Bhattarai

    Engineering and Applied Sciences PhD Program, University of Massachusetts, Dartmouth, United States
    Competing interests
    No competing interests declared.
  5. Bernat Olle

    Vedanta Biosciences, Inc, Cambridge, United States
    Competing interests
    Bernat Olle, Is the Chief Executive Officer of Vedanta Biosciences, Inc.
  6. Jason M Norman

    Vedanta Biosciences, Inc, Cambridge, United States
    Competing interests
    Jason M Norman, Is employee of Vedanta Biosciences, Inc.
  7. Wataru Suda

    Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  8. Kenshiro Oshima

    Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
    Competing interests
    No competing interests declared.
  9. Masahira Hattori

    Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
    Competing interests
    No competing interests declared.
  10. Georg K Gerber

    Massachusetts Host-Microbiome Center, Department of Pathology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    Georg K Gerber, Is a member of the Scientific Advisory Board of Kaleido, Inc.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9149-5509
  11. Chris Sander

    Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  12. Kenya Honda

    Center for Integrative Medical Sciences, RIKEN Institute, Yokohama City, Japan
    Competing interests
    Kenya Honda, Is a Co-Founder and Scientific Advisory Board Member of Vedanta Biosciences, Inc. Has received support from Vedanta Biosciences, Inc. under research agreements with his institution.
  13. Vanni Bucci

    Engineering and Applied Sciences PhD Program, University of Massachusetts, Dartmouth, United States
    For correspondence
    vanni.bucci@umassd.edu
    Competing interests
    Vanni Bucci, Has received support from Vedanta Biosciences, Inc. under research agreement with his institution.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3257-2922

Funding

National Institutes of Health (P41 GM103504)

  • Richard R Stein
  • Chris Sander

Brigham and Women's Hospital (Precision Medicine Initiative)

  • Georg K Gerber

Defense Advanced Research Projects Agency (BRICS award HR0011-15-C-0094)

  • Georg K Gerber

Human Frontier Science Program (RGP00055/2015)

  • Chris Sander

Takeda Science Foundation

  • Kenya Honda

National Institute of General Medical Sciences (5R01 GM106303)

  • Chris Sander

Japan Agency for Medical Research and Development

  • Kenya Honda

National Institute of Allergy and Infectious Diseases

  • Vanni Bucci

National Science Foundation

  • Vanni Bucci

Core Research for Evolutional Science and Technology

  • Kenya Honda

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: 11-strain time-series mouse experiments were performed under ethical approval by RIKEN, Keio and Azabu Universities under protocol H24-9(14) (RIKEN). 4-strain validation mouse work was performed at Brigham and Women's Hospital in Boston, MA in the Massachusetts Host Microbiome Center under IACUC protocol 2016N000141.

Copyright

© 2018, Stein et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 8,019
    views
  • 1,372
    downloads
  • 71
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Richard R Stein
  2. Takeshi Tanoue
  3. Rose L Szabady
  4. Shakti K Bhattarai
  5. Bernat Olle
  6. Jason M Norman
  7. Wataru Suda
  8. Kenshiro Oshima
  9. Masahira Hattori
  10. Georg K Gerber
  11. Chris Sander
  12. Kenya Honda
  13. Vanni Bucci
(2018)
Computer-guided design of optimal microbial consortia for immune system modulation
eLife 7:e30916.
https://doi.org/10.7554/eLife.30916

Share this article

https://doi.org/10.7554/eLife.30916

Further reading

    1. Computational and Systems Biology
    Masaaki Uematsu, Jeremy M Baskin
    Tools and Resources

    Plasmid construction is central to life science research, and sequence verification is arguably its costliest step. Long-read sequencing has emerged as a competitor to Sanger sequencing, with the principal benefit that whole plasmids can be sequenced in a single run. Nevertheless, the current cost of nanopore sequencing is still prohibitive for routine sequencing during plasmid construction. We develop a computational approach termed Simple Algorithm for Very Efficient Multiplexing of Oxford Nanopore Experiments for You (SAVEMONEY) that guides researchers to mix multiple plasmids and subsequently computationally de-mixes the resultant sequences. SAVEMONEY defines optimal mixtures in a pre-survey step, and following sequencing, executes a post-analysis workflow involving sequence classification, alignment, and consensus determination. By using Bayesian analysis with prior probability of expected plasmid construction error rate, high-confidence sequences can be obtained for each plasmid in the mixture. Plasmids differing by as little as two bases can be mixed as a single sample for nanopore sequencing, and routine multiplexing of even six plasmids per 180 reads can still maintain high accuracy of consensus sequencing. SAVEMONEY should further democratize whole-plasmid sequencing by nanopore and related technologies, driving down the effective cost of whole-plasmid sequencing to lower than that of a single Sanger sequencing run.

    1. Biochemistry and Chemical Biology
    2. Computational and Systems Biology
    Shinichi Kawaguchi, Xin Xu ... Toshie Kai
    Research Article

    Protein–protein interactions are fundamental to understanding the molecular functions and regulation of proteins. Despite the availability of extensive databases, many interactions remain uncharacterized due to the labor-intensive nature of experimental validation. In this study, we utilized the AlphaFold2 program to predict interactions among proteins localized in the nuage, a germline-specific non-membrane organelle essential for piRNA biogenesis in Drosophila. We screened 20 nuage proteins for 1:1 interactions and predicted dimer structures. Among these, five represented novel interaction candidates. Three pairs, including Spn-E_Squ, were verified by co-immunoprecipitation. Disruption of the salt bridges at the Spn-E_Squ interface confirmed their functional importance, underscoring the predictive model’s accuracy. We extended our analysis to include interactions between three representative nuage components—Vas, Squ, and Tej—and approximately 430 oogenesis-related proteins. Co-immunoprecipitation verified interactions for three pairs: Mei-W68_Squ, CSN3_Squ, and Pka-C1_Tej. Furthermore, we screened the majority of Drosophila proteins (~12,000) for potential interaction with the Piwi protein, a central player in the piRNA pathway, identifying 164 pairs as potential binding partners. This in silico approach not only efficiently identifies potential interaction partners but also significantly bridges the gap by facilitating the integration of bioinformatics and experimental biology.